Multiple weekend sessions
Getting Patients to BP Goals:
More Combo Therapy
Despite the well established link between hypertension and mortality, more than two-thirds of Europeans with high blood pressure (BP) receive no antihypertensive therapy and no more than 10% of patients reach goal BP values (<140 mm Hg SBP and <90 mm Hg DBP).
MORE>> |
Clinical Trial
Intensive Blood Pressure Control Improves Renal Survival in Pediatric Kidney Disease Patients
Similarly to adults, children with kidney disease commonly face progression to renal failure once a threshold of renal impairment is reached. A 2-year study of children up to age 18 found that blood pressure (BP) and proteinuria correlate with progression of chronic renal failure (CRF). (1) This, too, is similar to adult nephropathies where BP levels are closely associated with progressive renal failure. Studies in adults have suggested renoprotective effects of rigorous BP control, especially with renin-angiotensin system antagonists.
MORE>> |
|
 |
Clinical Trial
ONTARGET: The Ongoing Telmisartan Alone
and in Combination with Ramipril Global Endpoint Trial
ONTARGET: ACE or ARB? Or both?
In high-risk patients without heart failure who could not tolerate ACE inhibitors, the angiotensin-receptor blocker (ARB) telmisartan is equally effective in reducing cardiovascular risk as the ACE inhibitor ramipril and less likely to cause angioedema. However, while dual blockade with both an ARB and ACE inhibitor produced a larger biologic effect in terms of greater blood pressure lowering and an increase in the number of patients showing a potassium level >5.5 mmol/l, the combination was associated with more adverse events.
MORE>> |
|
